Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study of Autologous Anti-CD45 CAR T Cells in Combination With CD45 Base Edited HSPCs in Patients With Relapsed or Refractory Hematologic Malignancies

NCT07451054 is registered in ClinicalTrials.gov with University of Pennsylvania as lead sponsor.

NCT NCT07451054
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07451054 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study of Autologous Anti-CD45 CAR T Cells in Combination With CD45 Base Edited HSPCs in Patients With Relapsed or Refractory Hematologic Malignancies
Lead sponsor
University of Pennsylvania
Phase
Phase 1
Overall status
Recruiting
Start date
August 5, 2026
Completion date
July 31, 2051
Enrollment
42 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell non-hodgkin lymphoma (nhl), hodgkin lymphoma, richter's transformation, t-cell non-hodgkin lymphoma